DST-102

DST-102 is an ultra long-acting product candidate being developed by DelSiTech for the treatment of metabolic diseases, including type 2 diabetes and obesity. The candidate utilizes DelSiTech's proprietary Silica Matrix technology, a biodegradable drug delivery platform that enables the sustained release of active pharmaceutical ingredients—specifically a glucagon-like peptide 1 (GLP-1) receptor agonist—over several months from a single subcutaneous injection. This approach is designed to improve patient adherence and provide stable therapeutic drug levels, addressing the significant unmet needs in chronic metabolic disease management by reducing the frequency of administration compared to current daily or weekly therapies.